Fluoroquinolone/metronidazole pulsatile - MiddleBrook
Alternative Names: Fluoroquinolone/metronidazole PULSYS™ - MiddleBrook; Pulsatile fluoroquinolone/metronidazole - MiddleBrookLatest Information Update: 26 Aug 2009
At a glance
- Originator Advancis Pharmaceutical
- Developer MiddleBrook Pharmaceuticals
- Class
- Mechanism of Action DNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 26 Aug 2009 No development reported - Preclinical for Bacterial infections in USA (PO)
- 28 Jun 2007 Advancis Pharmaceutical is now called MiddleBrook Pharmaceuticals
- 31 Dec 2003 Preclinical trials in Bacterial infections in USA (PO)